Physician profile
Cameron Selent
NPI 1295119865
$5,540.00
in general payments reported to CMS, 2019-2025
21 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 79% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $296 · 2021: $1,011 · 2022: $954 · 2023: $898 · 2024: $1,262 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.09 |
| Education | $219.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,106.88 | 2020-2025 | Arikayce |
| Viiv Healthcare Company | $879.07 | 2020-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $573.45 | 2020-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $541.18 | 2019-2025 | Biktarvy |
| Melinta Therapeutics, LLC | $376.90 | 2021-2025 | Kimyrsa, Rezzayo, Vabomere |
| Abbvie INC. | $365.12 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Astellas Pharma US INC | $348.06 | 2023-2025 | Cresemba |
| Shionogi INC | $296.98 | 2021-2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $240.15 | 2021-2025 | Nuzyra |
| Janssen Products, LP | $184.94 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $125.25 | 2022-2025 | Rebyota |
| Theratechnologies INC. | $119.09 | 2021-2024 | Egrifta, Trogarzo |
| La Jolla Pharmaceutical Company | $111.43 | 2021-2025 | Xacduro, Zevtera |
| Janssen Biotech, INC. | $77.02 | 2021-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $50.49 | 2024-2025 | Vibativ |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $44.86 | 2023 | Mytesi |
| Mayne Pharma Commercial LLC | $34.71 | 2021 | |
| Vyera Pharmaceuticals, LLC | $18.06 | 2020 | |
| Allergan, INC. | $17.12 | 2020 | |
| Pfizer INC. | $14.80 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Selent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.